Overview
Pharmaceutical

ROHTO PHARMACEUTICAL CO.,LTD.

Rohto Pharmaceutical is a leading Japanese health and beauty care company engaged in the development, manufacture, and sale of eye care products (eye drops, eyewash), skin care products (topical medicines, lip care, sunscreen, functional cosmetics), and internal use products (gastrointestinal medicines, Kampo herbal medicines, supplements). The company operates globally through its Mentholatum brand across Asia, the Americas, and Europe, serving both OTC pharmaceutical and consumer health markets. Rohto differentiates itself through strong R&D capabilities spanning ophthalmology, dermatology, and regenerative medicine, combined with a broad international distribution network.

Market Cap
¥635B
US$4.05B
EV
¥572B
US$3.65B
Stock¥2,809.5▼-1.47%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
9.7
x
LTM EV/EBIT
12.8
x
LTM PER
19.2
x
LTM PBR
2.1
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-7.0%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Aug 7, 26FY2027 guidance raised: net profit +3%, driven by strong 'Hada Labo' sales
MC → EV Bridge
635BUS$4.05BMarket Cap62.0BUS$396M+ Debt84.8BUS$541M− Cash58.6BUS$374M− Inv. Sec.19.0BUS$121M+ NCI572BUS$3.65BEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
200US$1.27B'22/3239US$1.52B'23/3271US$1.73B'24/3309US$1.97B'25/3344US$2.19B'26/3
EBITDA 5Y (¥B)
36.6US$233M'22/341.4US$264M'23/348.3US$308M'24/350.6US$322M'25/356.4US$360M'26/3
Net Income 5Y (¥B)
21.0US$134M'22/326.4US$168M'23/330.9US$197M'24/331.0US$198M'25/334.2US$218M'26/3
Capital Structure
83%
EquityD/E 0.20xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
101US$644M21.4US$136M'22/3114US$724M11.7US$74.6M'23/3134US$852M10.5US$66.9M'24/3124US$788M54.0US$345M'25/3143US$910M64.2US$409M'26/3
Shareholders
Top 10 hold 39.6%
1
The Master Trust Bank of Japan, Ltd. (Trust Account)
13.46%
2
STATE STREET BANK AND TRUST COMPANY 505223 (Standing Proxy: Mizuho Bank, Ltd.)
5.44%
3
Custody Bank of Japan, Ltd. (Trust Account)
4.92%
4
Yamada Kousan Ltd.
3.72%
5
MUFG Bank, Ltd.
3.36%
6
Yamasho Kosan Co., Ltd.
2.23%
7
Nippon Life Insurance Company
1.87%
8
STATE STREET BANK AND TRUST COMPANY 505001 (Standing Proxy: Mizuho Bank, Ltd.)
1.61%
9
Kiyoko YAMADA
1.60%
10
Employee Stock Ownership Association
1.35%
Management
19 officers
Kunio YAMADA
Representative Director, Chairman
Apr 1980 Joined the Company Jun 1991 Director Jun 1992 Senior Managing Director Mar 1995 General Manager, Healthcare Business Promotion Headquarters May 1995 Director, Mentholatum Company Jun 1996 Senior Vice President, Director Jul 1998 Chairman, Director, Mentholatum Company Jun 1999 Representative Director, President Jun 2009 Representative Director, Chairman; Chief Executive Officer (CEO) Aug 2018 Representative Director, Chairman and President Jun 2019 Representative Director, Chairman (current) Mar 2021 Outside Director, Bacchus Bio Innovation Co., Ltd.
1956-01-23
Hidetoshi SEGI
Representative Director, President
Apr 1985 Joined Nippon Vicks K.K. (now P&G Japan G.K.) Jun 1997 Joined the Company Jun 2018 Director Mar 2022 Chief Strategy Officer (CSO) Jun 2022 Director Jun 2023 Managing Director Jun 2025 Representative Director, President (current)
1962-07-18
Masaya SAITO
Senior Vice President, Director, Chief Financial Officer (CFO)
Apr 1986 Joined the Company May 1998 President, Rohto Mentholatum (Vietnam) Co., Ltd. Apr 2008 Deputy General Manager, Business Information Headquarters Jun 2011 Director; General Manager, Corporate Planning Headquarters Jun 2017 Director, Business Strategy Promotion Headquarters Jun 2018 Senior Vice President, Director (current); President, Mentholatum Company (current); Chairman, Rohto Mentholatum (Vietnam) Co., Ltd. (current) Mar 2022 Chief Financial Officer (CFO) (current)
1963-11-01
Shinichi KUNISAKI
Senior Vice President, Director, Chief Technical Officer (CTO)
Apr 1981 Joined Suntory Ltd. (now Suntory Holdings Ltd.) Jan 2007 Joined the Company; Executive Officer, R&D Headquarters, in charge of development Feb 2007 General Manager, R&D Headquarters Jun 2010 Director Jun 2017 Director, Business Strategy Promotion Headquarters Jun 2018 Representative Director, President, Qualitech Pharma Co., Ltd. Jun 2020 Managing Director; E.Designer, Production and SCM Strategy Design Headquarters Mar 2022 Chief Technical Officer (CTO) (current) Jun 2023 Senior Vice President, Director (current)
1955-10-27
Yoko FUJIMOTO
Managing Director, Chief Medical Officer (CMO)
Apr 1992 Resident Physician, Neurology, Tokyo Metropolitan Neurological Hospital and Tokyo Metropolitan Bokutoh Hospital, among others Aug 1997 Research Fellow, Department of Immunology, Duke University (U.S.) Apr 2001 Resident Physician, Neurology, Tokyo Medical and Dental University Hospital (now Institute of Science Tokyo), among others Jul 2002 Joined Pharmacia K.K. (now Pfizer Japan Inc.); General Manager, R&D Clinical Development Planning; General Manager, Medical Affairs Division, among other positions Sep 2019 Director, Executive Officer; Head of Vaccine Division Jun 2025 Joined the Company; Managing Director (current); Chief Medical Officer (CMO) (current)
1965-12-17
Yasunori KAWASAKI
Director, Chief Human Resources Officer (CHRO)
Apr 1982 Joined Nippon Life Insurance Company Apr 1986 Joined the Company Oct 2011 Director, Michinoku Mirai Fund Foundation (current) Jul 2021 Executive Officer Mar 2023 In charge of human resource development and education Jun 2023 Director (current); Chief Human Resources Officer (CHRO) (current) Jun 2024 Outside Director, Morishita Jintan Co., Ltd. (current)
1960-02-26
Masae YAMANAKA
Director, Chief Transformation Officer (CXO)
Apr 1987 Joined IBM Japan, Ltd. Feb 2009 Joined Microsoft Japan Co., Ltd. Jul 2014 Joined LIXIL Corporation Jul 2017 Joined Panasonic Corporation; Managing Executive Officer, Connected Solutions Company (now Panasonic Connect Co., Ltd.) Oct 2017 Director, Executive Officer, Senior Vice President, Panasonic System Solutions Japan Co., Ltd. (now Field Solutions Company) Jun 2021 Outside Director, Sanrio Co., Ltd. (current) Jun 2022 Outside Director, JTB Corp. (current) May 2024 Joined the Company Jun 2024 Director (current); Chief Transformation Officer (CXO) (current)
1963-09-30
Yoichi HOMMA
Director, Chief Scientific Officer (CScO)
Apr 1992 Joined the Company May 2012 Deputy General Manager, R&D Headquarters Jun 2018 Director, Business Strategy Headquarters May 2019 Special Project General Manager, R&D Promotion Jul 2021 Executive Officer Jun 2024 Director (current); Chief Scientific Officer (CScO) (current)
1968-04-29
Noriko SUENOBU
Director, Chief Research Officer (CRO)
Apr 1991 Joined POLA Chemical Industries, Inc. Jan 2015 Executive Officer, Research Planning Jan 2018 Director and Executive Officer in charge of research, POLA Chemical Industries, Inc.; Executive Officer, Group Research, IP and Regulatory Affairs Center, POLA ORBIS Holdings Inc. Aug 2023 Representative Director, President, POLA Medical Inc. Apr 2025 Joined the Company; E.Designer, Strategy Design Headquarters (current) Jun 2025 Director (current); Chief Research Officer (CRO) (current)
1966-12-18
Akihide IRIYAMA
Director
Apr 1998 Joined Mitsubishi Research Institute, Inc. Aug 2003 Left Mitsubishi Research Institute, Inc. Aug 2008 Assistant Professor, School of Management, State University of New York at Buffalo (U.S.) Aug 2013 Associate Professor, Waseda Business School Apr 2019 Professor, Waseda Business School (current) Jun 2019 Director of the Company (current) Jun 2020 Outside Director, Sanoh Industrial Co., Ltd. (current) Dec 2020 Outside Director, Septeni Holdings Co., Ltd. (current) Jun 2021 Outside Director (Audit and Supervisory Committee Member), SORACOM, Inc. (current)
1972-12-08
Haruka MERA
Director
Jul 2014 Founded READYFOR Inc.; Representative Director, CEO (current) Jun 2020 Director of the Company (current)
1987-10-20
Eriko HAYASHI
Director
Oct 2001 Registered as attorney-at-law; joined Ohebashi LPC Jun 2007 Registered as New York attorney Jan 2010 Partner, Ohebashi LPC Jun 2010 Chief Representative, Shanghai Office, Ohebashi LPC Mar 2019 Outside Corporate Auditor, Kaizen Platform, Inc. (current) Nov 2019 Established Eri Law Office; Representative (current) Dec 2019 Outside Director, Change Inc. (now Change Holdings, Inc.) Aug 2021 Representative Partner, ERIO (current) Mar 2022 Outside Corporate Auditor, Mujin, Inc. (current) Jun 2022 Director of the Company (current)
1976-08-14
Maiko KATADA
Director
May 2005 Joined University of Tokyo Edge Capital Co., Ltd. (now UTEC Partners Co., Ltd.) May 2023 Visiting Researcher, Institute for Future Initiatives, University of Tokyo Jul 2023 Adviser, University of Tokyo Co-Creation Platform Development Co., Ltd. Apr 2024 Representative Director, Infinite CORE Inc. (now Red Capital Inc.) (current) Jun 2024 Director of the Company (current)
1975-03-17
Shoichiro IWATA
Director
Mar 1973 Joined Lion Oil & Fat Co., Ltd. (now Lion Corporation) Mar 1986 Joined PLUS Corporation Mar 1997 President, Representative Director, ASKUL Corporation May 2000 President, Representative Director and Chief Executive Officer (CEO), ASKUL Corporation Jun 2006 Outside Director, Shiseido Company, Limited Apr 2008 Vice Chairman, Japan Association of Corporate Executives Sep 2019 Established Force Marketing & Management Co., Ltd.; Representative Director, CEO (current) Aug 2020 Outside Director, Safie Inc. (current) Jun 2021 Outside Director, S.T. Corporation (current) Sep 2021 Outside Director, Arithmer Inc. (current) May 2022 Outside Director, Hacobu, Inc. (current) Jun 2025 Director of the Company (current)
1950-08-14
Masanori KIMURA
Full-time Corporate Auditor
Apr 1982 Joined the Company May 2000 Chief Manager, Corporate Services Department May 2003 Executive Officer; Deputy General Manager, Business Information Headquarters; General Manager, Human Resources and General Affairs Department Jul 2004 General Manager, Production Business Headquarters Jun 2005 Director May 2008 General Manager, Business Information Headquarters May 2009 General Manager, Healthcare Business Headquarters May 2013 General Manager, Agri-Farm Business Division Jun 2016 Corporate Auditor (current)
1957-11-29
Hideto KAMIMURA
Full-time Corporate Auditor
Apr 1982 Joined the Company May 2003 Deputy General Manager, Business Development Headquarters Apr 2009 Deputy General Manager, R&D Headquarters May 2010 Executive Officer May 2015 Senior Executive Officer; General Manager, Marketing Headquarters Jun 2017 Director, Business Strategy Promotion Headquarters Jun 2018 Director; General Manager, Ueno Techno Center Jun 2020 Corporate Auditor (current)
1958-07-19
Yasuhiro TANI
Corporate Auditor
Oct 1981 Joined Asahi Accounting Firm (now Azusa Audit LLC) Apr 1985 Registered as Certified Public Accountant Apr 1986 Established Tani Certified Public Accountant Office; Representative (current) May 2003 Registered as Certified Tax Accountant Apr 2006 Professor, Globis Graduate School of Management (current) Jun 2020 Corporate Auditor of the Company (current) Mar 2021 Outside Director (Audit and Supervisory Committee Member), Noritz Corporation Jun 2024 Outside Director (Audit and Supervisory Committee Member), Fuji Oil Group Holdings Inc. (now Fuji Oil Holdings Inc.) (current) Jul 2025 Lead Outside Director (Audit and Supervisory Committee Member), Noritz Corporation (current)
1956-10-11
Eri SUGIYAMA
Corporate Auditor
Oct 2001 Registered as attorney-at-law; joined Habatake Sogo Law Office Nov 2008 Joined Financial Services Agency as term-appointed staff; Securities Examiner, Inspection Bureau General Affairs Division Jul 2013 Partner Attorney, Habatake Sogo Law Office (current) Jun 2018 Outside Corporate Auditor, Shin-Meiwa Industry Co., Ltd. Apr 2022 Professor of Legal Practice, Kobe University Graduate School of Law Jun 2023 Outside Director, Linical Co., Ltd. Jun 2024 Corporate Auditor of the Company (current) Jun 2025 Outside Director (Audit and Supervisory Committee Member), Shin-Meiwa Industry Co., Ltd. (current); Outside Director (Audit and Supervisory Committee Member), Linical Co., Ltd. (current) Outside Corporate Auditor, Zenhoren Co., Ltd. (current)
1975-07-10
Asuka TERADA
Corporate Auditor
Oct 2001 Registered as attorney-at-law; joined Kyowa Sogo Law Office Apr 2018 Established N&T Law Office; Co-Representative Attorney (current) Aug 2019 Outside Corporate Auditor, D&M Company Inc. (current) Jun 2021 Outside Director, Denkyo Group Holdings Co., Ltd. (current) Apr 2024 Visiting Professor, Kyoto University Law School (current) Jun 2025 Corporate Auditor of the Company
1974-01-14
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-06
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-19
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-02-12
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-14
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-06
Q1 Earnings Flash
FY ending Mar 2026
EDINETAmended
2025-07-11
Amended Annual Securities Report
Period: Apr 2024 – Mar 2025
EDINET
2025-06-25
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-12
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-14
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-07
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-28
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-13
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-29
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-14
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-06-28
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-11
Quarterly Securities Report
EDINET
2021-06-25
Annual Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →